CD274와 Indoleamine 2,3-Dioxygenase를 통한 양수줄기세포의 면역조절능
의약학 > 의공학
이승희 ( Seung Hee Lee ) , 조현정 ( Hyun Jung Cho ) , 서장수 ( Jang Soo Suh ) , 유지 ( James J Yoo ) , 손윤희 ( Yun Hee Shon )
조직공학과 재생의학 2013년, 제10권 70~75페이지(총6페이지)
2a800646.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    135원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Abstract :Amniotic fluid-derived stem cells (AFSCs) might be an alternative and less-invasive source of mesenchymal stem cells (MSCs) that could be used in regenerative medicine. AFSCs share the similar immunosuppressive properties with MSCs derived from bone marrow. However, the mechanisms behind the immune responses of AFSCs remain unclear. In this paper, we investigated inhibitory effect of AFSCs on immune cells proliferation induced by mitogen. Measurement of IFN-γ levels in the culture supernatants revealed a significant decrease of the cytokine when mitogen-activated peripheral blood mononuclear cells (PBMCs) were cultured in the presence of AFSCs. AFSCs constitutively expressing HLA-ABC and CD274 increased the expression levels of them with the treatment of IFN-γ. Whereas, HLA-DR, HLA-G and co-stimulatory molecules such as CD80, CD86 were not expressed. Moreover, IFN-γ treatment also induced the expressions of indoleamine 2,3-dioxygenase (IDO), transforming growth factor-β (TGF-β) and IL-10 in AFSCs. Treatment with IDO inhibitor and anti-CD274 reverted the modulatory effect of the AFSCs. From these data, we suggest that AFSCs carry the immunomodulatory characteristics mediated by CD274 and IDO. Findings obtained from this study could be utilized for the development of amniotic fluid-derived stem cell therapy products with the further study.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.